The expression assessment of the estrogen, progesterone and HER2 receptors in selected malignant tumors of the salivary glands
Journal Title: Otolaryngologia Polska - Year 2013, Vol 67, Issue 5
Abstract
Introduction: The incidence of the malignant tumors of the salivary glands is relatelively low. However, rapid locoregional progression, distant metastases occurrence and high local recurrence rate occurring despite radical surgical treatment, significantly affect the outcome. Malignant tumors of the salivary glands are characterized by low radiosensitivity and poor response to systemic therapy. Therefore there is a need for new targeted therapies which may improve the prognosis. In some aspects, malignant tumors of the salivary glands are similar to breast cancers. Efficacy of hormonal replacement therapy and the treatment with the monoclonal antibody (trastuzumab) in the treatment of breast cancer is well known and confirmed. Criterion determining the qualification for treatment is the presence of hormone receptors and HER2 receptors in the tumor. Aim: The aim of this study was to evaluate the expression of estrogen receptor, progesterone receptor and HER2 in selected salivary gland malignancies. Materials and methods: Study group consisted of 51 patients with the salivary glands cancer. In the study group there were 42 tumors in the parotid gland, 7 tumors of the submandibular gland, 1 in the mucosa of the cheek and 1 tumor in the tongue. Histologically material comprised of muco-epidermoid carcinoma (10), adenoid-cystic carcinoma (8), salivary duct (7), adenocarcinoma (6), squamous cell carcinoma (6), mioepithelial carcinoma (5) and other (9). In all cases immunohistochemical analysis of the estrogen receptor, progesterone receptor and HER2 receptor was performed. Results: The expression of the estrogen receptor was found in 18% of tumors (9 patients). The expression of the progesterone receptor was found in 20% (10 patients). HER2 expression was found in 10% of tumors and was related to only one histological type of tumor – salivary duct carcinoma. Conclusion: HER2 expression in malignant tumors of the salivary glands, especially in salivary duct carcinoma may be of use in future implementation of new targeted therapies based on monoclonal antibodies.
Authors and Affiliations
Wojciech Golusiński, Anna Wegner, Paweł Trzeciak, Marcin Sówka, Andrzej Kopczyński, Małgorzata Bromboszcz
Keywords
Related Articles
- EP ID EP52212
- DOI -
- Views 89
- Downloads 0
The report of the realization of the Universal Neonatal Hearing Screening Program in Poland between 2003 and 2015
.
Myringoplastyka u dzieci – czynniki wpływające na wynik leczenia chirurgicznego
Objective. Myringoplasty is successfully performed in children since many years. However still considerable controversy surrounds the subject of proper timing of surgery and other factors influencing the success rate. Th...
Reoperacje w otosklerozie
The authors present 68 cases of revision stapes surgery in otosclerosis. This review analyzed intraoperative findings and postrevision hearing results. According to our observations, the most common causes of failure aft...
Ocena epidemiologiczna nowotworów gruczołów ślinowych u pacjentów leczonych w Klinice Otolaryngologii we Wrocławiu w latach 2001–2010
Salivary gland tumors represents approxima tely 3% of all head and neck neoplasms. Most of them are benign and located in the parotid gland. Aim: Epidemologic analysis of salivary gland neoplasms in the Wrocław ENT Depar...
Ocena przydatności wybranych testów przedsionkowych w postępowaniu diagnostycznym i leczniczym u chorych z niewydolnością tętnic kręgowych i podstawnej